IZERVAY Drug Patent Profile
✉ Email this page to a colleague
When do Izervay patents expire, and when can generic versions of Izervay launch?
Izervay is a drug marketed by Astellas and is included in one NDA. There are six patents protecting this drug.
This drug has one hundred and sixteen patent family members in thirty countries.
The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this compound. Additional details are available on the avacincaptad pegol sodium profile page.
DrugPatentWatch® Generic Entry Outlook for Izervay
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be November 11, 2026. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for IZERVAY
IZERVAY is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of IZERVAY is ⤷ Start Trial.
This potential generic entry date is based on patent 8,236,773.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 11,491,176 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 8,236,773 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Astellas | IZERVAY | avacincaptad pegol sodium | SOLUTION;INTRAVITREAL | 217225-001 | Aug 4, 2023 | RX | Yes | Yes | 11,273,171 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for IZERVAY
See the table below for patents covering IZERVAY around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2006214437 | Aptamer therapeutics useful in the treatment of complement-related disorders | ⤷ Start Trial |
| Brazil | PI0607002 | aptámeros terapêuticos úteis no tratamento de desordens relacionadas a complemento | ⤷ Start Trial |
| Canada | 2597889 | AGENTS THERAPEUTIQUES A BASE D'APTAMERES UTILES DANS LE TRAITEMENT DE TROUBLES LIES AU COMPLEMENT (APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch